Essential Fatty Acid Deficiency with SMOFlipid Reduction in an Infant with Intestinal Failure-Associated Liver...

Area of Science:

• Nutritional Science
• Pediatric Gastroenterology
• Clinical Nutrition

Background:

• Multicomponent lipid emulsions like SMOFlipid offer intermediate essential fatty acids (EFAs) compared to soybean or fish-oil based options.
• Intestinal failure-associated liver disease (IFALD) management often involves lipid emulsion therapy.

Observation:

• A case study identified moderate essential fatty acid deficiency (EFAD) and poor weight gain in an infant receiving reduced SMOFlipid (1 g/kg/d).
• The infant had intestinal failure-associated liver disease.

Findings:

• Increasing SMOFlipid dosage to 2-3 g/kg/d normalized EFA levels in the infant.
• Adequate growth resumed, and cholestasis resolved upon increasing SMOFlipid dosage.

Implications:

• Reduced SMOFlipid doses increase the risk of EFAD in infants with IFALD.
• Conventional SMOFlipid doses are sufficient to reverse cholestasis and support growth, making dose reduction unnecessary.